Vivalis, GlaxoSmithKline Win OK For First Human Trial With EB66

Published: Nov 24, 2010

PARIS Nov 24 (Reuters) - French biotech Vivalis (VLS.PA) and its British partner GlaxoSmithKline (GSK.L) have won U.S. clearance to begin testing for the first time on humans flu vaccines that were produced using Vivalis's technology.

Back to news